醫美概念股再度走強 朗姿股份、奧園美谷雙雙漲超8%
格隆匯10月13日丨醫美概念股再度走強,金髮拉比漲停,朗姿股份、奧園美谷漲超8%,悦心健康、澳洋健康、貝泰妮、愛博醫療等跟漲。朗姿股份昨日公吿,預計前三季度淨利潤1.47億元-1.65億元,同比增長194.04%-230.04%;第三季度淨利潤5368.31萬元-7168.31萬元,同比增長1.54%-35.58%。國信證券指出,繼續關注行業長期成長性及確定性突出且短期基本面增長具有較強支撐的醫美龍頭,隨着監管加碼打擊違法市場,以及合規產品供給加碼,具備較為豐富的產品矩陣,以及較強渠道營銷能力的產品供應商有望實現長期高速成長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.